본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose GC1118 is a novel antibody targeting epidermal growth factor receptor (EGFR) with enhanced blocking activity against both low- and high-affinity EGFR ligands. A phase 1b/2a study was conducted to determine a recommended phase 2 dose (RP2D) of GC1118 in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) (phase 1b) and to assess the safety and efficacy of GC1118 plus FOLFIRI as a second-line therapy for recurrent/metastatic colorectal cancer (CRC) (phase 2a). Materials and Methods Phase 1b was designed as a standard 3+3 dose-escalation study with a starting dose of GC1118 (3 mg/kg/week) in combination with biweekly FOLFIRI (irinotecan 180 mg/m²; leucovorin 400 mg/m²; 5-fluorouracil 400 mg/m² bolus and 2,400 mg/m² infusion over 46 hours) in patients with solid tumors refractory to standard treatments. The subsequent phase 2a part was conducted with objective response rate (ORR) as a primary endpoint. Patients with KRAS/NRAS/BRAF wild-type, EGFR-positive, recurrent/metastatic CRC resistant to the first-line treatment were enrolled in the phase 2a study. Results RP2D of GC1118 was determined to be 3 mg/kg/wk in the phase 1b study (n=7). Common adverse drug reactions (ADRs) observed in the phase 2a study (n=24) were acneiform rash (95.8%), dry skin (66.7%), paronychia (58.3%), and stomatitis (50.0%). The most common ADR of ≥ grade 3 was neutropenia (33.3%). ORR was 42.5% (95% confidence interval [CI], 23.5 to 62.0), and median progression-free survival was 6.7 months (95% CI, 4.0-8.0). Conclusion GC1118 administered weekly at 3 mg/kg in combination with FOLFIRI appears as an effective and safe treatment option in recurrent/metastatic CRC.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Applicability of spatial technology in cancer research Sangjeong Ahn, Hye Seung Lee p. 343-356

Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2021 Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, Community of Population-Based Regional Cancer Registries p. 357-371

Prediction of cancer incidence and mortality in Korea, 2024 Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo p. 372-379

Health inequities in cancer incidence according to economic status and regions are still existed even under universal health coverage system in Korea : a nationwide population based study using National Health Insurance Database Youngs Chang, Soo-Hee Hwang, Sang-A Cho, Hyejin Lee, Eunbyul Cho, Jin Yong Lee p. 380-403

Impact of patient sex on adverse events and unscheduled utilization of medical services in cancer patients undergoing adjuvant chemotherapy : a multicenter retrospective cohort study Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim ... [et al.] p. 404-413

Radiation oncologists’ perspectives on oligometastatic disease : a Korean survey study Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn p. 414-421

(The) real-world outcome of first line atezolizumab in extensive-stage small cell lung cancer : a multicenter prospective cohort study Myeong Geun Choi, Yeon Joo Kim, Jae Cheol Lee, Wonjun Ji, In-Jae Oh, Sung Yong Lee, Seong Hoon Yoon, Shin Yup Lee, Jeong Eun Lee, Eun Young Kim, Chang-Min Choi p. 422-429

Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer : implications for thoracic radiotherapy Dowook Kim, Hak Jae Kim, Hong-Gyun Wu, Joo Ho Lee, Suzy Kim, Tae Min Kim, Jin-Soo Kim, Byoung Hyuck Kim p. 430-441

Genomic landscape of pulmonary sarcomatoid carcinoma Hyun Jung Kwon, Sejoon Lee, Yeon Bi Han, Jeonghyo Lee, Soohyeon Kwon, Hyojin Kim, Jin-Haeng Chung p. 442-454

Tissue and plasma-based highly sensitive blocker displacement amplicon nanopore sequencing for EGFR mutations in lung cancer Patinya Akkhasutthikun, Pornchai Kaewsapsak, Pattaraporn Nimsamer, Pavit Klomkliew, Suthida Visedthorn, Pragwalai Chanchaem, Chinachote Teerapakpinyo, Sunchai Payungporn, Sutima Luangdilok p. 455-463

Development of the Korean association for lung cancer clinical practice guidelines : recommendations on radial probe endobronchial ultrasound for diagnosing lung cancer : an updated meta-analysis Soo Han Kim, Hyun Sung Chung, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Insu Kim, Jung Seop Eom p. 464-483

Revolutionizing non–small cell lung cancer diagnosis : ultra-high-sensitive ctDNA analysis for detecting hotspot mutations with long-term stored plasma Ji-Young Lee, Seyeon Jeon, Ha Ra Jun, Chang Ohk Sung, Se Jin Jang, Chang-Min Choi, Sung-Min Chun p. 484-501

Clinical effect of endosonography on overall survival in patients with radiological N1 non-small cell lung cancer Bo-Guen Kim, Byeong-Ho Jeong, Goeun Park, Hong Kwan Kim, Young Mog Shim, Sun Hye Shin, Kyungjong Lee, Sang-Won Um, Hojoong Kim, Jong Ho Cho p. 502-512

Pyrotinib combined with vinorelbine in patients with previously treated HER2-positive metastatic breast cancer : a multicenter, single-arm, prospective study Kuikui Jiang, Ruoxi Hong, Wen Xia, Qianyi Lu, Liang Li, Jianhao Huang, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Xin An ... [et al.] p. 513-521

Temporal trend in uptake of the national general health checkups and cancer screening program among Korean women with breast cancer Thi Xuan Mai Tran, Soyeoun Kim, Chihwan Cha, Boyoung Park p. 522-530

Implication of pre- and post-radiotherapy ctDNA dynamics in patients with residual triple-negative breast cancer at surgery after neoadjuvant chemotherapy : findings from a prospective observational study Tae Hoon Lee, Haeyoung Kim, Yeon Jeong Kim, Woong-Yang Park, Won Park, Won Kyung Cho, Nalee Kim p. 531-537

Genomic characteristics and its therapeutic implications in breast cancer patients with detectable molecular residual disease Shu Zhang, Yan Jiang, Lu Zhou, Jing Xu, Gang Zhang, Lu Shen, Yan Xu p. 538-548

Assessment of eligibility and utilization of accelerated partial breast irradiation (APBI) in Korean breast cancer patients (KROG 22-15) Seok-Joo Chun, Ji Hwan Jo, Yong Bae Kim, Sangjoon Park, Sung-Ja Ahn, Su Ssan Kim, Kyubo Kim, Kyung Hwan Shin p. 549-556

PD-L1 (SP142) expression in primary and recurrent/metastatic triple-negative breast cancers and its clinicopathological significance Eun Kyung Han, Ji Won Woo, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park p. 557-566

Neoadjuvant nivolumab therapy for esophageal squamous cell carcinoma : a single-arm, phase Ⅱ study Sehhoon Park, Yurimi Lee, Jiyun Lee, Yang Won Min, Hong Kwan Kim, Joon Young Choi, Hyun Ae Jung, Yong Soo Choi, Yoon-La Choi, Young Mog Shim, Jong-Mu Sun p. 567-579

NESC multicenter phase Ⅱ trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel-cisplatin-5FU+lenograstim) followed by chemoradiation based 5FU and oxaliplatin and surgery Laurent Mineur, Frederi Plat, Françoise Desseigne, Gael Deplanque, Mohamed Belkacemi, Laurence Moureau-Zabotto, Carlos D. Beyrne, Khadija Jalali, Stéphane Obled, Denis Smith, Léa Vazquez, Rania Boustany p. 580-589

(A) phase 1b/2a study of GC1118 with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with recurrent or metastatic colorectal cancer Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim ... [et al.] p. 590-601

(A) single-arm phase Ⅱ study of nab-paclitaxel plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang, Miao Chen, Wei Cao, Hongfeng Gou, Qing Zhu p. 602-615

Physical activity and bladder cancer risk : findings of the Japan collaborative cohort study Hang An, Keyang Liu, Kokoro Shirai, Ryo Kawasaki, Akiko Tamakoshi, Hiroyasu Iso p. 616-623

Clinical outcomes of small cell carcinoma of the genitourinary tract and the prognostic significance of the tumor immune microenvironment Jaewon Hyung, Hyung-Don Kim, Gi Hwan Kim, Yong Mee Cho, Yeon-Mi Ryu, Sang-Yeob Kim, Inkeun Park, Shinkyo Yoon, Jae Lyun Lee p. 624-633

Oncological outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide with versus without confirmatory bone scan Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon ... [et al.] p. 634-641

Tandem high-dose chemotherapy increases the risk of secondary malignant neoplasm in pediatric solid tumors Hana Lim, Minji Im, Eun Seop Seo, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Sung Yoon Cho, Jong-Won Kim, Do Hoon Lim, Ki Woong Sung, Ji Won Lee p. 642-651

Long-term outcomes of protocol-based treatment for newly diagnosed medulloblastoma Won Kee Ahn, Seung Min Hahn, Hong In Yoon, Jeongshim Lee, Eun Kyung Park, Kyu Won Shim, Dong Seok Kim, Chang-Ok Suh, Se Hoon Kim, Chuhl Joo Lyu, Jung Woo Han p. 652-664

Case series of soft tissue sarcoma patients with brain metastasis with implications from genomic and transcriptomic analysis Changhee Park, Rokhyun Kim, Jaeyong Choi, Miso Kim, Tae Min Kim, Ilkyu Han, Jong-Il Kim, Han-Soo Kim p. 665-674

(A) phase Ⅱ study to evaluate the efficacy of bortezomib in combination with thalidomide in treatment : naïve waldenstrom macroglobulinemia patients Ja Min Byun, Junghoon Shin, Sang-A Kim, Hyunkyung Park, Jiyun Lee, Dong-Yeop Shin, Junshik Hong, Jeong-Ok Lee, Soo-Mee Bang, Inho Kim, Sung-Soon Yoon, Youngil Koh p. 675-680

Pembrolizumab for patients with relapsed or refractory extranodal NK/T-cell lymphoma in Korea Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee p. 681-687

Assessment of bone marrow involvement in extranodal NK/T-cell lymphoma : positron emission tomography versus bone marrow biopsy, and the significance of minimal involvement by EBV+ cells (KROG 18-09) Tae Hoon Lee, Hyun Ju Kim, Jong Hoon Lee, Jeongshim Lee, Jin Hee Kim, Dongryul Oh, Keun-Yong Eom p. 688-696

참고문헌 (18건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Biomaterials. 2013 Nov;34(34):8690-707 미소장
2 Oncotarget. 2015 Sep 22;6(28):24780-96 미소장
3 JAMA. 2021 Feb 16;325(7):669-685 미소장
4 Curr Drug Targets. 2021;22(9):998-1009 미소장
5 Int J Cancer. 2021 Apr 5;: 미소장
6 Clin Colorectal Cancer. 2015 Jun;14(2):72-80 미소장
7 Oncologist. 2019 Aug;24(8):1037-e636 미소장
8 Cancers (Basel). 2020 Oct 31;12(11): 미소장
9 Int J Mol Sci. 2019 Nov 24;20(23): 미소장
10 J Clin Oncol. 2010 Nov 1;28(31):4706-13 미소장
11 Mol Cancer Ther. 2016 Feb;15(2):251-63 미소장
12 Control Clin Trials. 1989 Mar;10(1):1-10 미소장
13 J Exp Clin Cancer Res. 2021 Oct 18;40(1):328 미소장
14 Basic Clin Pharmacol Toxicol. 2017 Mar;120(3):243-249 미소장
15 Clin Transl Sci. 2021 May;14(3):990-1001 미소장
16 N Engl J Med. 2008 Oct 23;359(17):1834-6 미소장
17 Gastric Cancer. 2019 Sep;22(5):932-940 미소장
18 Clin Exp Immunol. 2009 Oct;158(1):1-9 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차